The report’s authors assessed commercial plan coverage and formulary design concerning biosimilars for the top 25 payers—covering approximately 189 million lives—in the United States, using publicly available policies.
Avalere has issued a new report that finds that utilization management strategies, including preferential formulary design and step therapy, are impacting the uptake of biosimilars in the United States.
While the Congressional Budget Office (CBO) in 2009 projected that the United States could achieve a $5.9 billion savings from biosimilars over 10 years, Avalere estimates the actual savings realized since the inception of the US biosimilars pathway at just $241 million, or 8% of the CBO’s projection for the period. (Notably, the savings estimate includes savings from tbo-filgrastim, which was not approved as a biosimilar but as a follow-on version of filgrastim.) While there are multiple factors at work that have led to somewhat disappointing cost-savings, the report suggests that payer policies are playing a significant role.
The report’s authors assessed commercial plan coverage and formulary design concerning biosimilars for the top 25 payers—covering approximately 189 million lives—in the United States, using publicly available policies. For each plan, they sought to determine the order of therapy (or step therapy) for biosimilars or other products in a given indication. Namely, they identified whether a particular product was the preferred first step, whether a patient had to use that product for a specified period of time before changing to the next preferred step or steps, and whether there were exceptions allowed.
Of the plans reviewed, 18 had available documents related to infliximab and its biosimilars:
The report highlights the fact that, in many cases of step therapy that require a patient to start with a reference biologic, the biosimilar of the same product will only be covered if the patient fails to respond adequately to the reference. This practice, they note, contradicts the European League Against Rheumatism’s recommendations that switching to another drug—not a biosimilar of the same drug—may be appropriate in the case of treatment failure.
The same 18 plans had medical benefit information available for filgrastim and its biosimilar (Avalere did not include tbo-filgrastim in this portion of the analysis):
The authors write that, while it is to be expected that payers will act to protect their short- to medium-term cost-savings interests by employing utilization management strategies to biosimilars, “The extent to which such policies are necessary, will continue to be put in place, and/or will be effective, remains to be seen,” and the clinical appropriateness of such policies will need to be evaluated.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.